1487PLURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer. (23rd October 2018) - Yoh, K; Seto, T; Satouchi, M; Nishio, M; Yamamoto, N; Murakami, H; Nogami, N; Kuroda, S; Nomura, S; Sato, A; Tsuchihara, K; Kohno, T; et al.